Characteristics of AML patients with normal karyotype
. | Total . | NPMwt . | NPMm . | P . |
|---|---|---|---|---|
| No. patients | 106 | 56 | 50 | |
| Median age, y (range) | 44 (17-65) | 46 (17-65) | 43 (20-65) | .61 |
| Sex, M/F | 57/49 | 29/27 | 28/22 | .70 |
| Median WBC count, × 109 cells/L (range) | 39 (1-453) | 18 (1-158) | 69 (1-453) | <.001 |
| FAB, no. (%) | ||||
| M0 | 9 | 8 (89) | 1 (11) | .03 |
| M1 | 34 | 17 (50) | 17 (50) | .83 |
| M2 | 19 | 14 (74) | 5 (26) | .07 |
| M4 | 19 | 7 (37) | 12 (63) | .009 |
| M5 | 20 | 7 (35) | 13 (65) | |
| M6 | 2 | 2 (100) | 0 (0) | .50 |
| NC | 3 | 1 (33) | 2 (66) | .60 |
| Mutations, no. (%) | ||||
| FLT3/ITD | 33 (31) | 14 (25) | 19 (38) | .21 |
| CEBPAm | 20 (19) | 15 (27) | 5 (10) | .05 |
| MLL/PTD | 3 (3) | 2 (4) | 1 (2) | .99 |
| Outcome | ||||
| CR, no. (%) | 92 (87) | 49 (88) | 43 (86) | .99 |
| 6-y OS ± SE, % | 41 ± 11 | 37 ± 16 | 43 ± 15 | .83 |
| 6-y RFS ± SE, % | 40 ± 12 | 34 ± 17 | 47 ± 17 | .64 |
| 6-y EFS ± SE, % | 29 ± 10 | 26 ± 14 | 32 ± 14 | .24 |
. | Total . | NPMwt . | NPMm . | P . |
|---|---|---|---|---|
| No. patients | 106 | 56 | 50 | |
| Median age, y (range) | 44 (17-65) | 46 (17-65) | 43 (20-65) | .61 |
| Sex, M/F | 57/49 | 29/27 | 28/22 | .70 |
| Median WBC count, × 109 cells/L (range) | 39 (1-453) | 18 (1-158) | 69 (1-453) | <.001 |
| FAB, no. (%) | ||||
| M0 | 9 | 8 (89) | 1 (11) | .03 |
| M1 | 34 | 17 (50) | 17 (50) | .83 |
| M2 | 19 | 14 (74) | 5 (26) | .07 |
| M4 | 19 | 7 (37) | 12 (63) | .009 |
| M5 | 20 | 7 (35) | 13 (65) | |
| M6 | 2 | 2 (100) | 0 (0) | .50 |
| NC | 3 | 1 (33) | 2 (66) | .60 |
| Mutations, no. (%) | ||||
| FLT3/ITD | 33 (31) | 14 (25) | 19 (38) | .21 |
| CEBPAm | 20 (19) | 15 (27) | 5 (10) | .05 |
| MLL/PTD | 3 (3) | 2 (4) | 1 (2) | .99 |
| Outcome | ||||
| CR, no. (%) | 92 (87) | 49 (88) | 43 (86) | .99 |
| 6-y OS ± SE, % | 41 ± 11 | 37 ± 16 | 43 ± 15 | .83 |
| 6-y RFS ± SE, % | 40 ± 12 | 34 ± 17 | 47 ± 17 | .64 |
| 6-y EFS ± SE, % | 29 ± 10 | 26 ± 14 | 32 ± 14 | .24 |
NPMwt indicates NPM wild-type; NPMm, NPM mutation; NC, not classified; FLT3/ITD, FLT3 internal tandem duplication; CEBPAm, CEBPA mutation; MLL/PTD, MLL partial tandem duplication; CR, complete remission; OS, overall survival; RFS, relapse-free survival; EFS, event-free survival.